Recipharm, a CDMO, has recently seen an increase in demand for its product Klorokinfosfat RPH Pharma marketed in Sweden by Astimex Pharma. The company has also received questions about the product, which is typically used to treat patients with malaria prophylaxis and rheumatoid arthritis.

The interest in this product is due to chloroquine’s antiviral effects, which has potential to be used to treat patients with coronavirus COVID-19 associated pneumonia. Chloroquine has been included by WHO as one drug treatment option for priority research connected to immediate goals.

Although Klorokinfosfat RPH Pharma is not approved as an antiviral agent or for use in relation to pneumonia, Recipharm is presently focusing on securing supply of its chloroquine product should demand suddenly increases and new recommendations are introduced.